Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08057418 · 1 trial · 1 indication
Assessment of TEAEs, SAEs, clinical laboratory values, vital signs, continuous cardiac monitoring and 12-lead ECGs
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will receive single oral solution or tablet dose(s) of placebo. |
| PF-08057418 | EXPERIMENTAL | Participants will receive single oral solution or tablet dose(s) of PF-08057418 |
| Name | Type | Description |
|---|---|---|
| PF-08057418 | DRUG | solution or tablet (fasted/fed) |
| Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.) | OTHER | solution or tablet (fasted/fed) |
Inclusion Criteria: * Adults 18 to 60 years of age (or the minimum age of consent per local regulations) at screening. * Healthy participants, as determined by medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) between 16 and 32 kg/m² a...
PF-08057418 is an investigational small molecule being studied for use in healthy adults. It is currently in Phase 1 clinical development, with a completed trial evaluating how a single dose is tolerated in the body. It is not approved for any condition and remains under investigation.
PF-08057418 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule in healthy adult participants.
PF-08057418 is in Phase 1 clinical development. A Phase 1 trial has been completed, which studied how a single dose of the medicine is tolerated in healthy adults. The drug is investigational and has not been approved by regulatory authorities.
PF-08057418 has one completed Phase 1 clinical trial registered as NCT07575906. The study, titled "A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults," enrolled 8 participants in the United States. It was a randomized, double-blind, placebo-controlled trial.
PF-08057418 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed to evaluate its tolerability in healthy adults, but the drug has not received regulatory approval for any use.